Pure red cell aplasia associated with dapsone therapy [3]

Annals of Pharmacotherapy

Volumn 39, Issue 6, 2005, Pages 1137-1138

  Borrás Blasco, Joaquín ^a   Conesa García, Venancio ^a   Navarro Ruiz, Andrés ^a   Devesa, Pedro ^a   Matarredona, Jaime ^a   Marín Jiménez, Francisca ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; GLIBENCLAMIDE;

AGED; ASTHENIA; BLOOD CELL COUNT; BLOOD TRANSFUSION; CASE REPORT; CLINICAL FEATURE; GRANULOMA ANNULARE; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; MALE; MULTINUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SKIN BIOPSY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD TRANSFUSION; DAPSONE; GRANULOMA ANNULARE; HUMANS; MALE; RED-CELL APLASIA, PURE; TREATMENT OUTCOME;

EID: 18844413821     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E349     Document Type: Letter

References (6)

1. Masuda M, Saitoh H, Mizoguchi H. Clonality of acquired primary pure red cell aplasia. Am J Hematol 1999;62:193-5.
2. Thompson DF, Gales MA. Drug-induced pure red cell aplasia. Pharmacotherapy 1996;16:1002-8.
3. Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995;26:461-7.
4. Uetrecht J, Zahid N, Shear NH, Biggar WD. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther 1988;245:274-9.
5. Nicholls MD, Concannon AJ. Maloprim-induced agranulocytosis and red-cell aplasia. Med J Aust 1982;2:564-6.
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.